Drug DUI and Drugged Driving Laws in the U.S.

Drugged driving — operating a motor vehicle while impaired by a controlled substance, prescription medication, or over-the-counter drug — is prosecuted under DUI statutes in all 50 states, though the specific legal standards, testing protocols, and per se thresholds vary significantly across jurisdictions. Unlike alcohol-impaired driving, which anchors on the 0.08% blood alcohol concentration (BAC) standard codified federally through the 1995 National Highway System Designation Act, drug DUI lacks a single nationally uniform impairment threshold. This page covers the legal definitions, evidentiary mechanics, classification distinctions, contested tensions, and reference frameworks that govern drugged driving prosecutions across U.S. jurisdictions.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Drug DUI refers to the criminal offense of operating or being in actual physical control of a motor vehicle while impaired by any substance other than alcohol — or in combination with alcohol — to a degree that renders the driver incapable of safe operation. The offense is captured under different statutory labels across states: "driving under the influence of drugs" (DUID), "driving while impaired" (DWI), "operating while intoxicated" (OWI), and "driving under the influence of an intoxicant" (DUII). The National Highway Traffic Safety Administration (NHTSA) formally defines drug-impaired driving as impairment caused by any legal or illegal substance affecting the central nervous system.

The scope of covered substances is broad. Federal scheduling under the Controlled Substances Act (CSA), 21 U.S.C. § 801 et seq., classifies drugs into five schedules based on accepted medical use and abuse potential, and state DUI statutes generally incorporate CSA scheduling or define their own covered substance lists. Covered categories commonly include:

• Schedule I controlled substances (heroin, MDMA, psilocybin)
• Schedule II substances (cocaine, methamphetamine, oxycodone)
• Cannabis and THC metabolites (regardless of medical or recreational legality at the state level)
• Prescription medications (benzodiazepines, opioid analgesics, muscle relaxants)
• Over-the-counter substances (antihistamines, certain sleep aids)
• Inhalants and volatile compounds

For a side-by-side comparison of how states define impairment across substances, see DUI Laws by State.

Core Mechanics or Structure

Drug DUI prosecutions rest on two distinct evidentiary frameworks that states apply independently or in combination.

Impairment-Based Standard
Under the impairment standard, the prosecution must demonstrate that the defendant's ability to drive was actually impaired by a drug — regardless of the measured concentration of that drug in blood or urine. Evidence typically includes officer observations documented in the arrest report (erratic driving pattern, slurred speech, dilated or pinpoint pupils, lack of coordination), results of standardized field sobriety tests (SFSTs), and the opinion of a Drug Recognition Expert (DRE).

NHTSA developed the Drug Evaluation and Classification (DEC) Program in the 1970s through a collaboration with the Los Angeles Police Department. The DEC protocol — now administered in partnership with the International Association of Chiefs of Police (IACP) — involves a 12-step evaluation conducted by a certified DRE officer. The 12 steps include breath alcohol testing, interview of the arresting officer, preliminary examination, eye examinations (HGN, VGN, lack of convergence), divided attention tests, vital signs measurement, darkroom examinations, muscle tone assessment, injection site examination, and toxicological examination. As of NHTSA's published program data, more than 8,000 DRE-certified officers are active across the United States (NHTSA DEC Program).

Per Se Drug DUI Standard
Sixteen states have enacted per se drug DUI laws that establish specific nanogram thresholds for THC or other controlled substances in blood, triggering automatic presumption of impairment if exceeded, without requiring additional behavioral evidence. For example, Washington State's RCW § 46.61.502 sets a per se threshold of 5 nanograms of THC per milliliter of whole blood. Montana, Nevada, Ohio, Pennsylvania, and Virginia maintain zero-tolerance per se standards for Schedule I substances, meaning any detectable concentration constitutes the offense.

Chemical testing in drug DUI cases differs from breathalyzer protocols used for alcohol. Blood draws remain the primary collection method, as urine and oral fluid (saliva) testing have distinct detection windows and metabolite profiles that complicate direct impairment correlation. The admissibility standards for blood evidence in DUI cases are analyzed further at Blood Test DUI Admissibility.

Causal Relationships or Drivers

The legal complexity of drug DUI cases is driven by pharmacokinetic factors — how specific substances are absorbed, distributed, metabolized, and eliminated by the body — combined with an absence of a universal impairment biomarker equivalent to BAC.

Pharmacokinetic Variation
THC, the primary psychoactive compound in cannabis, distributes rapidly into fatty tissue after inhalation, producing blood concentrations that drop sharply within 1–3 hours even as impairment persists. THC-COOH, an inactive metabolite, remains detectable in urine for 3–30 days in regular users, creating a gap between detected presence and actual impairment at the time of driving. The National Institute on Drug Abuse (NIDA) notes that THC's psychomotor effects on driving — including slower reaction time and impaired lane tracking — peak well before blood concentrations peak.

Polydrug Use
Polydrug scenarios — where a driver combines alcohol with cannabis, opioids, or benzodiazepines — compound impairment unpredictably. NHTSA research shows that combining alcohol with cannabis produces additive and sometimes synergistic impairment effects exceeding either substance alone, complicating both field evaluation and toxicological interpretation.

Prescription Drug Complexity
For prescription drug DUI cases, tolerance developed through therapeutic use can dissociate blood concentration from behavioral impairment. A patient stabilized on a benzodiazepine regimen may exhibit normal driving behavior at blood concentrations that would severely impair a drug-naive individual, yet still face per se prosecution in zero-tolerance jurisdictions. The distinct legal landscape for these cases is detailed at Prescription Drug DUI.

Classification Boundaries

Drug DUI charges stratify based on substance type, prior offense history, and aggravating circumstances — producing misdemeanor or felony classifications with materially different penalties.

Misdemeanor vs. Felony
First and second drug DUI offenses are misdemeanors in most states, carrying penalties including fines, license suspension, mandatory drug education programs, and possible jail time of up to 12 months. Third or subsequent offenses typically elevate to felony status. Several states — including Arizona and Georgia — classify any DUI causing injury as a felony regardless of offense number. The general framework for this distinction is covered at DUI Felony vs. Misdemeanor.

Aggravated Circumstances
Drug DUI becomes an aggravated charge when combined with factors such as: a child passenger under a specified age (commonly 14 or 16), a BAC or drug concentration multiple times the per se threshold, speeding 20+ mph over the posted limit, or driving on a suspended license. Aggravated DUI Charges provides a fuller breakdown of enhancement triggers by state.

Zero-Tolerance Drug Provisions
Seventeen states maintain zero-tolerance policies for drivers under age 21 regarding any detectable controlled substance, separate from adult standards. Federal highway funding conditions under 23 U.S.C. § 161 have historically influenced state adoption of zero-tolerance alcohol provisions; zero-tolerance drug standards emerged through state legislative action independent of a direct federal mandate.

Commercial Drivers
Commercial driver's license (CDL) holders face stricter standards. Federal Motor Carrier Safety Administration (FMCSA) regulations at 49 CFR Part 382 require controlled substance testing for CDL operators and disqualify drivers who test positive from operating commercial motor vehicles. Covered substances under DOT testing panels include marijuana metabolites, cocaine, amphetamines, opioids, and phencyclidine (PCP). The specific CDL consequences framework is addressed at Commercial Driver DUI.

Tradeoffs and Tensions

No Universal THC Impairment Threshold
The core scientific tension in drug DUI law is the absence of a validated THC-to-impairment relationship analogous to the 0.08% BAC standard. The National Academies of Sciences, Engineering, and Medicine's 2017 report on cannabis and health concluded that substantial evidence exists for cannabis impairing driving performance, but also that blood THC concentration is a poor predictor of impairment level due to variable individual tolerance and pharmacokinetic profiles. Critics of per se THC thresholds — including the American Civil Liberties Union (ACLU) — argue that fixed nanogram limits produce prosecutions of unimpaired drivers, particularly chronic medical cannabis users.

DRE Testimony Admissibility
DRE opinions are admitted in courts across most states, but the scientific foundation of DRE evaluation has been contested in Daubert and Frye hearings. Defense challenges focus on inter-rater reliability and the absence of controlled double-blind validation studies for the full 12-step protocol. DUI Expert Witnesses covers the framework under which expert testimony is evaluated.

Federalism and Cannabis Legalization
As of 2024, 24 states and the District of Columbia have legalized adult-use cannabis (National Conference of State Legislatures), yet cannabis remains a Schedule I controlled substance under federal law. This creates a framework tension: lawful cannabis consumption under state law does not insulate a driver from federal law enforcement on federal property or from state-level drug DUI prosecution.

Common Misconceptions

Misconception: A medical marijuana card prevents drug DUI prosecution.
Correction: State medical cannabis authorization does not create a defense to drug DUI. Impairment at the time of driving remains the operative legal standard regardless of lawful possession or use status. Arizona's Supreme Court in State v. Harris (2015) upheld that medical marijuana authorization does not preclude per se THC prosecution.

Misconception: Drug DUI requires proof of illegal drug use.
Correction: Prescription medications and over-the-counter substances can support drug DUI charges if they produce impairment. No illicit activity is a required element; the impairment itself — from any substance — is the criminal conduct.

Misconception: Urine testing proves impairment at the time of driving.
Correction: Urine testing identifies metabolites, which may persist days to weeks after use. Courts and toxicologists widely acknowledge that a positive urine test establishes prior exposure, not contemporaneous impairment. Blood testing is the preferred evidentiary method specifically because it measures active substance concentration closer to the time of the event.

Misconception: Refusing a drug test avoids prosecution.
Correction: Implied consent laws in all 50 states impose administrative and criminal penalties for chemical test refusal, and refusal can be introduced as evidence of consciousness of guilt. Nineteen states allow warrantless blood draws from unconscious DUI suspects under the exigent circumstances doctrine as confirmed by Mitchell v. Wisconsin, 588 U.S. 840 (2019).

Checklist or Steps (Non-Advisory)

The following steps reflect the procedural sequence that drug DUI cases typically follow from stop through disposition, based on NHTSA DEC Program documentation and standard state criminal procedure frameworks.

1. Initial traffic stop or contact — Officer observes driving behavior (swerving, delayed reaction, improper lane use) or responds to collision; documents objective observations.
2. Preliminary alcohol screening (PAS) — Portable breath test administered at roadside to separate alcohol contribution from drug impairment.
3. Field sobriety test administration — Standardized Field Sobriety Tests (SFSTs) administered per NHTSA guidelines; results documented in officer's report.
4. DRE evaluation request — If SFSTs suggest drug impairment inconsistent with alcohol level, DRE-certified officer is summoned; 12-step evaluation conducted.
5. Arrest and implied consent advisement — Suspect arrested on probable cause; implied consent advisement provided regarding chemical testing consequences.
6. Chemical specimen collection — Blood drawn (or oral fluid collected where authorized) per state protocol; chain of custody documented for laboratory analysis.
7. Laboratory toxicology analysis — Certified forensic laboratory quantifies substance concentrations; results reported in ng/mL (blood) or ng/mL (oral fluid).
8. Charging decision — Prosecutor reviews arrest report, DRE evaluation, and toxicology results; charges filed under applicable state statute.
9. Arraignment and plea entry — Defendant arraigned; charges read; initial plea entered. See DUI Arraignment Process.
10. Pretrial motions — Defense may challenge chemical test admissibility, DRE opinion, or Fourth Amendment compliance. See DUI Pretrial Motions.
11. Trial or disposition — Case proceeds to trial or resolved through plea agreement; sentencing follows conviction.

Reference Table or Matrix

State THC Per Se Threshold Examples (NCSL State DUI Laws Database):